| Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 20859537 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this study was to evaluate the effect of levosimendan on mortality in cardiogenic shock (CS) after ST elevation myocardial infarction (STEMI). METHODS AND RESULTS: Data were obtained prospectively from the SCAAR (Swedish Coronary Angiography and Angioplasty Register) and the RIKS-HIA (Register of Information and Knowledge about Swedish Heart Intensive Care Admissions) about 94 consecutive patients with CS due to STEMI. Patients were classified into levosimendan-mandatory and levosimendan-contraindicated cohorts. Inotropic support with levosimendan was mandatory in all patients between January 2004 and December 2005 (n = 46). After the SURVIVE and REVIVE II studies were presented, levosimendan was considered contraindicated and was not used in consecutive patients between December 2005 and December 2006 (n = 48). The cohorts were similar with respect to pre-treatment characteristics and concomitant medications. There was no difference in the incidence of new-onset atrial fibrillation, in-hospital cardiac arrest and length of stay at the coronary care unit. There was no difference in adjusted mortality at 30 days and at one year. CONCLUSION: The use of levosimendan neither improves nor worsens mortality in patients with CS due to STEMI. Well-designed randomized clinical trials are needed to define the role of inotropic therapy in the treatment of CS. |
| | |
Authors:
|
Elmir Omerovic; Truls Råmunddal; Per Albertsson; Mikael Holmberg; Per Hallgren; Jan Boren; Lars Grip; Göran Matejka |
Related Documents
:
|
6822087 - Efficacy and safety of defibrillation with rectangular waves of 2- to 20-milliseconds d... 8615317 - Prospective randomized comparison of anodal monophasic shocks versus biphasic cathodal ... 19661807 - Right ventricular function in myocardial infarction complicated by cardiogenic shock: i... 19487927 - Preserved cerebral microcirculation during cardiogenic shock. 15217777 - Age is not a significant risk factor for failed trial of beta-blocker therapy in older ... 19628727 - Three-dimensional alignment of the aggregated myocytes in the normal and hypertrophic m... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-09-07 |
Journal Detail:
|
Title: Vascular health and risk management Volume: 6 ISSN: 1178-2048 ISO Abbreviation: Vasc Health Risk Manag Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-09-22 Completed Date: 2010-12-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101273479 Medline TA: Vasc Health Risk Manag Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 657-63 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. elmir@wlab.gu.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Atrial Fibrillation / etiology Cardiotonic Agents / therapeutic use* Chi-Square Distribution Cohort Studies Electrocardiography Female Heart Arrest / etiology Humans Hydrazones / therapeutic use* Length of Stay Male Myocardial Infarction / complications, drug therapy*, mortality Myocardial Revascularization Proportional Hazards Models Pyridazines / therapeutic use* Sex Factors Shock, Cardiogenic / drug therapy*, etiology, mortality Statistics, Nonparametric |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Image force microscopy of molecular resonance: A microscope principle.
Next Document: Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?